Descripción de la empresa
Equillium, Inc. operates as a clinical-stage biotechnology firm dedicated to the development of therapeutics designed to address severe autoimmune and inflammatory disorders, specifically targeting unmet medical needs within the United States healthcare landscape. The company functions within the broader healthcare sector, with its specific industry classification as biotechnology, a domain characterized by high research and development costs and significant regulatory hurdles before products reach market approval. Currently, the enterprise maintains a market capitalization of $121.39M, while specific figures for annual revenue and the total employee count are not disclosed in the available financial data. These valuation metrics indicate that the company holds a small-cap status, reflecting a business stage where value is predominantly derived from the potential of its pipeline rather than established commercial cash flows from product sales.
Salud financiera
The reported financial statements for the trailing twelve months show a net income of $-22,398,000 and an EBITDA of $-23,518,000, while revenue figures are not available for calculation. The substantial gap between the reported revenue (which is unavailable) and the significant net loss reveals a cost structure dominated by research expenses and operational overhead typical of clinical-stage entities that have not yet generated substantial commercial sales. The company reports a free cash flow of $-14,327,250, indicating that its current financial flexibility is constrained by heavy capital outflows required to advance its lead product candidate, Itolizumab (EQ001), through clinical trials. All three reported margins—gross margin, operating margin, and profit margin—are listed at 0.0%, a metric often observed in biotechnology companies during pre-commercialization phases where costs vastly exceed direct sales or where data is not yet standardized for reporting. On the balance sheet side, Equillium holds $30.28M in cash against $719,000 in debt, resulting in a debt-to-equity ratio of 2.51, which suggests a leveraged position relative to equity but one that is manageable given the cash reserves. The current ratio stands at 10.58, indicating a highly conservative stance regarding short-term liquidity where current assets significantly exceed current liabilities. Finally, the return on equity is -94.0% and the return on assets is -51.4%, metrics that reveal management is currently generating negative returns on the capital base as the firm invests heavily into R&D rather than distributing profits.
Evaluación de valoración
The trailing twelve-month P/E ratio is listed as N/A due to the company's lack of positive net income, while the forward P/E is reported at -9.29, implying that the market is pricing the stock based on anticipated future earnings rather than historical profitability. The price-to-book ratio is 4.13, suggesting that the market values the company at a significant premium over its book value, a common characteristic for biotech firms where intangible assets like intellectual property and pipeline potential are not fully captured on the balance sheet. Alternative valuation metrics such as the price-to-sales ratio are unavailable, and the EV/EBITDA stands at -3.90, further highlighting that traditional earnings-based valuation models are not applicable until the company transitions to profitability. The stock has traded within a 52-week range between a low of $0.27 and a high of $2.70, meaning the current price sits at the upper end of the historical trading band relative to the recent lows. The beta coefficient of 1.74 indicates that the stock price is significantly more volatile than the broader market, moving with greater intensity than the overall index in response to sector-specific news or general market fluctuations.
Growth & Income
Revenue growth and earnings growth rates for the year-over-year period are listed as N/A, precluding any quantitative comparison of whether earnings are growing faster or slower than revenue within the current reporting cycle. As a non-dividend payer, Equillium reports a dividend yield of N/A and a payout ratio of 0.0%, confirming that the company reinvests all available earnings and cash reserves back into its research and development initiatives rather than distributing income to shareholders. This reinvestment strategy is essential for clinical-stage companies to sustain operations and advance their pipeline candidates through the rigorous approval processes required by regulatory bodies. Consequently, the overall growth and income profile of Equillium, Inc. is defined by capital appreciation potential derived from pipeline milestones rather than current income generation or dividend distributions.